Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as ANEB-001
selonabant · 2 trials · 2 indications
Feeling High on a visual analog scale (mm)
Body sway (mm);
Alertness on a visual analog scale (mm)
Heart Rate in beats/min
The minimum possible Beck Depression Inventory (BDI) score is 0, and the maximum score is 63. This score is determined by summing the ratings from the 21 questions, with each question scoring from 0 to 3, indicating the severity of depressive symptoms over the past two weeks. Lower score means less depression
The Columbia-Suicide Severity Rating Scale (C-SSRS) does not have a single minimum or maximum score, as it is not a traditional cumulative-score test. Instead, it uses a series of "yes" or "no" questions to place an individual into distinct categories of risk based on their specific responses. Lower score means less suicidal ideation.
Pharmacokinetic clearance (\\(CL\\)) is a quantitative measure of how efficiently the body removes a drug from the bloodstream. It is defined as the volume of plasma from which a drug is completely and irreversibly removed per unit of time and is typically expressed in units like milliliters per minute (mL/min) or liters per hour (L/h).
| Arm | Type | Description |
|---|---|---|
| Part A - ANEB-001 | EXPERIMENTAL | Subjects receive THC and varying amounts of ANEB-001 |
| Part A - Placebo | PLACEBO_COMPARATOR | Subjects receive THC and placebo |
| Part B - Cohort 1 - ANEB-001 | EXPERIMENTAL | Subjects receive 21 mg of THC and 30 mg of ANEB-001 |
| Part B - Cohort 1 - Placebo | PLACEBO_COMPARATOR | Subjects receive 21 mg of THC and placebo |
| Part B - Cohort 2 - ANEB-001 | EXPERIMENTAL | Subjects receive 21 mg of THC and 10 mg of ANEB-001 |
| Part B - Cohort 2 - Placebo | PLACEBO_COMPARATOR | Subjects receive 21 mg of THC and placebo |
| Part B - Cohort 3 - ANEB-001 | EXPERIMENTAL | Subjects receive 21 mg of THC and 1 hour later, 30 mg ANEB-001 |
| Part B - Cohort 3 - Placebo | PLACEBO_COMPARATOR | Subjects receive 21 mg THC and 1 hour later, placebo |
| Part B - Cohort 4 - ANEB-001 | EXPERIMENTAL | Subjects receive 40 mg of THC and 1 hour later, 10 mg of ANEB-001 |
| Part B - Cohort 4 - Placebo | PLACEBO_COMPARATOR | Subjects receive 40 mg of THC and 1 hour later, placebo |
| Part B - Cohort 5 - ANEB-001 | EXPERIMENTAL | Subjects receive 30 mg of THC and 1 hour later, 10 mg of ANEB-001 |
| Part B - Cohort 5 - Placebo | PLACEBO_COMPARATOR | Subjects receive 30 mg of THC and 1 hour later, 10 mg of ANEB-001 |
| Part B - Cohort 6 - ANEB-001 | EXPERIMENTAL | Subjects will consume a high fat meal prior to receiving 30 mg of THC and 1 hour later, 10 mg of ANEB-001 |
| Part B - Cohort 6 - Placebo | PLACEBO_COMPARATOR | Subjects will consume a high fat meal prior to receiving 30 mg of THC and 1 hour later, placebo |
| Part C - Cohort 7 - ANEB-001 | EXPERIMENTAL | Subjects receive a 40 mg dose of THC and a 10 mg dose of ANEB-001 |
| Part C - Cohort 8 - ANEB-001 | EXPERIMENTAL | Subjects receive a 60 mg dose of THC and a 20 mg dose of ANEB-001 |
| Experimental Cohort 1 | EXPERIMENTAL | Single intravenous dose of 1 mg of selonabant or placebo |
| Experimental Cohort 2 | EXPERIMENTAL | Single intravenous dose of 2 mg of selonabant or placebo |
| Experimental Cohort 3 | EXPERIMENTAL | Single intravenous dose of 5 mg of selonabant or placebo |
| Experimental Cohort 4 | EXPERIMENTAL | Single intravenous dose of 10 mg of selonabant or placebo |
| Experimental Cohort 5 | EXPERIMENTAL | Single intravenous dose of 20 mg of selonabant or placebo |
| Name | Type | Description |
|---|---|---|
| ANEB-001 | DRUG | Experimental Treatment |
| Placebo | DRUG | Placebo comparator |
| selonabant | DRUG | Intravenous infusion of selonabant |
Inclusion Criteria: * Signed informed consent prior to any study-mandated procedure * BMI between 18 and 30 kg/m2 * Minimum weight 50 kg * Occasional cannabis user Exclusion Criteria: * Evidence of active or chronic condition that could interfere with, or which the treatment of might interfere wi...
Selonabant is an investigational small molecule being developed by Anebulo Pharmaceuticals, Inc. (ticker ANEB). It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific medical conditions it is intended to treat have not been disclosed.
Selonabant is being developed by Anebulo Pharmaceuticals, Inc., which trades under the ticker ANEB. The company is the sponsor of the clinical program for this small molecule.
Selonabant is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. It is an investigational drug and has not been approved by the FDA.
Selonabant has been evaluated in a single Phase 1 trial, NCT07211607, titled I.V. Selonabant in Healthy Adult Subjects. The trial was completed, enrolled 40 participants, and was conducted in the United States.
The molecular target of selonabant has not been disclosed. It is a small molecule, but no target or mechanism of action information is available.